90 Y-NM600 targeted radionuclide therapy induces immunologic memory in syngeneic models of T-cell Non-Hodgkin’s Lymphoma

摘要: Finding improved therapeutic strategies against T-cell Non-Hodgkin’s Lymphoma (NHL) remains an unmet clinical need. We implemented a theranostic approach employing tumor-targeting alkylphosphocholine (NM600) radiolabeled with 86Y for positron emission tomography (PET) imaging and 90Y targeted radionuclide therapy (TRT) of NHL. PET biodistribution performed in mouse models NHL showed vivo selective tumor uptake retention 86Y-NM600. An initial toxicity assessment examining complete blood counts, chemistry, histopathology major organs established 90Y-NM600 safety. Mice bearing tumors treated experienced growth inhibition, extended survival, high degree cure immune memory toward reestablishment. treatment was also effective disseminated tumors, improving survival rates. Finally, we observed key role the adaptive system potentiating durable anti-tumor response to TRT, especially presence microscopic disease. Hernandez et al. show effectiveness radionucleotide (NHL). This study suggests that delivering radiation all disease sites elicits minimal induces response, inviting combination therapies activating agents.